Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinity moves into autoimmune testing with $33m acquisition

This article was originally published in Clinica

Executive Summary

Irish diagnostics specialist Trinity Biotech has continued to expand its offering, this time diversifying into the autoimmune testing field with the acquisition of Immco Diagnostics for $32.75m. However, unlike its other more recent purchases, Sweden’s Fiomi Diagnostics (www.clinica.co.uk, 2 March 2012) and Phoenix Biotech in 2011, Trinity’s latest deal is not within point-of-care (POC) testing but sits in the more traditional lab diagnostics and services space. Trinity believes that there are synergies between Immco’s offering and its existing infectious disease testing portfolio.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel